Ultimately, STAT3, SRC, MAPK3, MAPK1, RELA, PTPN11, JUN, MAPK14, STAT1, and EGFR were identified as the core targets of YTG for the treatment of IPF (Table 2). Here, EGFR is linked to idiopathic pulmonary fibrosis.